Full-Time

Warehouse Operations Manager

Cell and Gene Therapy

Updated on 9/13/2026

Cencora

Cencora

10,001+ employees

Global pharmaceutical distribution and services provider

No salary listed

Brooks, KY, USA

In Person

Onsite in Brooks, Kentucky; relocation is required, and periodic travel may be required.

Bachelor's

Category
Warehouse & Fulfillment
Required Skills
Supply Chain Management
Word/Pages/Docs
Customer Service
Excel/Numbers/Sheets
Microsoft Outlook
PowerPoint/Keynote/Slides

Get referred to Cencora

See people who can refer or advise you

Requirements
  • A four-year bachelor's degree or equivalent combination of experience and education in business administration, supply chain, logistics, life sciences, operations management, or a similar field.
  • A minimum of two years of directly related and progressively responsible experience.
  • Working knowledge of warehouse operations, specialized handling procedures, and quality-focused processes in a regulated environment.
  • Ability to communicate effectively orally and in writing with clients, customers, and cross-functional internal partners.
  • Strong client relationship and customer service skills.
  • Strong project management skills with the ability to manage multiple priorities and deadlines in a fast-paced environment.
  • Strong organizational skills and attention to detail.
  • Ability to prioritize client expectations while balancing operational requirements, compliance obligations, and service commitments.
  • Ability to work effectively under tight deadlines and manage time-sensitive activities with urgency and accuracy.
  • Strong interpersonal and leadership skills.
  • Good analytical and mathematical skills.
  • Ability to meet deadlines.
  • Good decision-making skills.
  • Excellent problem-solving skills and ability to resolve issues effectively and efficiently.
  • Knowledge of computers and ability to operate Outlook, PowerPoint, Word, and Excel effectively.
  • Comfort working in highly specialized operational environments that may require enhanced personal protective equipment, strict handling procedures, and work in smaller or controlled spaces.
  • Strong understanding of product integrity, compliance, accuracy, and discretion when handling specialized, high-value therapies.
  • Willingness to work extended hours, split shifts, and some weekends as needed.
  • Willingness to relocate to meet business needs.
Responsibilities
  • Plan, coordinate, and manage specialized operations for handling, storage, preparation, and movement of cell and gene therapy products in a complex, controlled environment.
  • Promote Cencora’s purpose and guiding principles and develop a culture of inclusion, equity, and diversity in the Distribution Center.
  • Enable talent development and succession planning in the Distribution Center and across the network.
  • Direct cell and gene therapy operational processes to ensure safe, compliant, accurate, and efficient handling of specialized, high-value therapies.
  • Lead and collaborate across teams to prioritize projects and initiatives, solve problems, and drive continuous improvement and standardization.
  • Serve as an operational subject matter expert for Cell and Gene Therapy Solutions and support stakeholders on program requirements, workflows, and service expectations.
  • Act as a client-facing operational partner by communicating with customers and clients, providing updates, resolving issues, managing expectations, and ensuring responsive service.
  • Partner with Sales and cross-functional teams to support client needs, drive operational readiness, and execute cell and gene therapy program requirements.
  • Manage specialized product handling and workflow processes while ensuring adherence to product-specific requirements, chain of identity and chain of custody expectations, temperature-controlled handling standards, and critical quality and compliance measures.
  • Manage the operational clock through efficient use of labor and hours worked.
  • Support compliance with policies, procedures, safety rules, personal protective equipment requirements, security standards, and applicable regulatory requirements; maintain and coordinate all areas of security.
  • Monitor facility performance and productivity measures to maximize service quality, reduce risk, improve efficiency, and support operational excellence.
  • Act as a backup for the leadership team as necessary.
  • Review and monitor standard operating procedures and recommend improvements to customer experience, efficiency, accuracy, service, and cost.
  • Monitor staff performance to ensure compliance with policies, practices, client requirements, and approved standard operating procedures.
  • Supervise associate relations functions, including hiring, terminating, performance management, development, and training of warehouse associates.
  • Ensure Distribution Center equipment and specialized handling environments are maintained and in proper working order.
  • Establish and maintain positive working relationships with Distribution Center associates, clients, customers, and internal business partners.
  • Perform related duties as assigned.
  • Travel periodically based on business need.
Desired Qualifications
  • Experience supporting highly regulated, temperature-controlled, specialty pharmaceutical, biologics, healthcare logistics, or other specialized operational environments.

Cencora provides global pharmaceutical distribution and a range of services, including specialty pharmacy, consulting, supply-chain management, patient support programs, and data analytics for healthcare providers, manufacturers, and veterinary practices. It works by combining physical drug distribution with value-added services such as inventory management, regulatory compliance guidance, patient support, and data-driven insights to optimize supply chains and outcomes. The company differentiates itself with an integrated, end-to-end offering that spans distribution, clinical services, analytics, and advisory support to help clients run more efficient operations and lower costs. Its goal is to improve healthcare outcomes by delivering comprehensive pharmaceutical solutions that enable better care and lower overall expenses.

Company Size

10,001+

Company Stage

IPO

Headquarters

Pennsylvania

Founded

1907

Get referred to Cencora

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Fiscal 2026 Q3 revenue reached $84.8 billion, and EPS guidance rose to $17.75-$17.95.
  • Cencora completed OneOncology in February 2026, strengthening specialty-pharmacy and oncology economics.
  • A $7 billion revolver and $1 billion buyback show lenders and management backing execution.

What critics are saying

  • Opioid litigation still carries a $4.2 billion accrued liability through 2039.
  • Maryland courts vacated Baltimore's $152 million verdict, but appeals can revive distributor exposure.
  • ASP rule changes and 340B guidance threaten community-oncology margins by 2028, hitting OneOncology.

What makes Cencora unique

  • Cencora pairs drug distribution with OneOncology, deepening specialty-care workflow integration.
  • Its global network spans U.S. Healthcare Solutions and International Healthcare Solutions across 51,000 employees.
  • Nucleus inventory tools and cell-gene therapy enablement embed Cencora inside provider operations.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Paid Parental Leave

Adoption Assistance

Infertility Coverage

Family Planning Benefits

Behavioral Health Solutions

Professional Development Budget

Training Programs

Company News

Associated Press
Sep 2nd, 2026
Cencora launches cell and gene therapy service to help health systems scale advanced treatment programmes

Cencora has launched Cell and Gene Therapy Enablement through its Accelerate Pharmacy Solutions division to help health systems develop and expand cell and gene therapy programmes. The service provides support across financial planning, operational readiness, and scalable growth to reduce care barriers and improve patient access to advanced therapies. More than 35 cell and gene therapies have received FDA approval, with over 1,700 clinical trials underway globally. However, only 4% of health system pharmacy leaders report being fully prepared to integrate these treatments, highlighting infrastructure gaps. The offering includes market assessments, readiness evaluations, governance design, and workflow planning. Cencora, ranked number 10 on the Fortune 500 with over $300 billion in annual revenue, already provides specialty pharmaceutical services across the therapy lifecycle.

Yahoo Finance
Aug 14th, 2026
Cencora beats Q2 profit estimates as specialty pharma platform drives growth

Cencora reported second-quarter revenue of $84.75 billion, slightly above analyst estimates of $84.43 billion, representing 5.1% year-on-year growth. Adjusted earnings per share came in at $4.48, beating consensus estimates of $4.35 by 3%. Management attributed the performance to strength in specialty pharmaceuticals, particularly through Management Services Organisations like OneOncology and RCA. CEO Robert Mauch highlighted the company's positioning in specialty care, stating, "Our specialty platform supports growth across the healthcare ecosystem." The company raised its full-year adjusted EPS guidance to $17.85 at the midpoint. Operating margin held steady at 1.3%, matching the same quarter last year. During the earnings call, analysts questioned management about biosimilar opportunities, specialty logistics competition, and potential policy risks from proposed ASP rule changes.

Yahoo Finance
Aug 12th, 2026
Cencora raises FY2026 guidance after Q3 EPS jumps 12%, buys back $1B in shares

Cencora reported strong third-quarter results for fiscal year 2026, driven by execution across its business units and investments in its specialty positioning. The pharmaceutical distributor achieved double-digit adjusted operating income growth and 12% earnings per share growth in the quarter. The company conducted $1 billion in opportunistic share repurchases during the period. Based on its performance and confidence in continued execution, Cencora raised its fiscal 2026 EPS guidance. President and CEO Robert Mauch credited the results to the company's team members and their commitment to providing solutions for customers. He highlighted the strength of Cencora's portfolio and its pharmaceutical-centric strategy as the company approaches the end of its fiscal year. The earnings call was held on 5 August 2026, with senior leadership including Mauch and CFO Eva Boratto participating.

MarketScreener
Aug 5th, 2026
Cencora boosts credit facility to $7B, extends maturity to 2031

Cencora and its subsidiary Innomar Strategies have amended their credit agreement, increasing their multi-currency revolving credit facility from $5.5 billion to $7.0 billion. The facility's maturity date has been extended to July 2031. Interest rates on borrowings range from 69.5 to 110 basis points over various term rates, depending on Cencora's public debt ratings. The agreement includes covenants such as a maximum financial leverage ratio. Separately, on 31 July 2026, Cencora amended its receivables securitisation facility, reducing it from $1.5 billion to $1.0 billion whilst increasing the accordion feature from $500 million to $1.0 billion. This gives the company the option to expand commitments by up to $1.0 billion, subject to bank approval.

Yahoo Finance
Aug 1st, 2026
Cencora Q3 earnings preview: analysts expect $4.37 EPS on $84.89B revenue

Wall Street analysts expect Cencora to report quarterly earnings of $4.37 per share, marking a 9.3% year-over-year increase. Revenues are projected to reach $84.89 billion, up 5.2% from the same quarter last year. Over the past 30 days, the consensus earnings per share estimate has been revised upward by 1.3%. Analysts forecast revenue from Total US Healthcare Solutions at $75 billion, representing 2.9% year-over-year growth. International Healthcare Solutions revenue is expected to remain flat at $7.79 billion. Operating income projections show US Healthcare Solutions at $940.87 million and International Healthcare Solutions at $158.45 million. Cencora shares have risen 5.3% over the past month and hold a Zacks Rank of 2, indicating expected outperformance versus the broader market.